The lack of validated, distributed comprehensive genomic profiling assays for patients with
cancer inhibits access to precision oncology treatment. To address this, we describe elio …

Timely and accurate identification of molecular alterations in solid tumors is essential for
proper management of patients with advanced cancers. This has created a need for rapid …

As more clinically relevant cancer genes are identified, comprehensive diagnostic
approaches are needed to match patients to therapies, raising the challenge of optimization …

Abstract Knowledge of “actionable” somatic genomic alterations present in each tumor (eg,
point mutations, small insertions/deletions, and copy-number alterations that direct …

Massively parallel sequencing approaches are beginning to be used clinically to
characterize individual patient tumors and to select therapies based on the identified …

We developed and clinically validated a hybrid capture next generation sequencing assay to
detect somatic alterations and microsatellite instability in solid tumors and hematologic …

We developed and validated a clinical whole-genome and transcriptome sequencing
(WGTS) assay that provides a comprehensive genomic profile of a patient's tumor. The …

Tumor molecular profiling is becoming a standard of care for patients with cancer, but the
optimal platform for cancer sequencing remains undetermined. We established a …

We describe the analytic validation of NeXT Dx, a comprehensive genomic profiling assay to
aid therapy and clinical trial selection for patients diagnosed with solid tumor cancers …

Background As knowledge of mechanisms that drive the development of cancer grows,
there has been corresponding growth in therapies specific to a mechanism. While these …